Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 904 • 2014 ACR/ARHP Annual Meeting
Ultrasound Synovitis Reflects Synovial Inflammation at a Histopathological Level
Nora Ng, Stephen Kelly, Frances Humby, Maria DiCicco, Vidalba Rocher, Rebecca Hands, Michele Bombardieri and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: Ultrasound (US) is widely used by rheumatologists to assess inflammatory burden on patients with inflammatory arthritis. Some studies have shown that US measures of…
Abstract Number: 2144 • 2014 ACR/ARHP Annual Meeting
Cuantification of Hand Bone Mineral Density By Radiogrammetry and Dual X-Ray Absorptiometry in Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez*¹, Saturnino González Ortega², Ana M. Ortiz-García¹, Eugenio Escolano², Esther Vicente-Rabaneda¹, Rosario Garcia-Vicuña³, Isidoro González-Alvaro³ and Santos Castañeda-Sanz⁴, ¹Rheumatology Department, Hospital Universitario de La Princesa, Madrid, Spain, ²Radiology Department, Hospital Universitario de la Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain
Background/Purpose: The evaluation of cortical bone mineral density (BMD) on metacarpal bones by digital radiogrammetry (DXR) has been proven to be a simple, reliable and…
Abstract Number: 423 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Pieter Meyer², Bridget Hodkinson³, Eustasius Musenge⁴, Gregory Tintinger², Mohammed Tikly⁵ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²university of pretoria, pretoria, South Africa, ³Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ⁴University of Witwatersrand, Johannesburg, South Africa, ⁵Rheumatology Wits University, C H Baragwanath Hospital, Johannesburg, South Africa
Background/Purpose Serial measurement of circulating anti-citrullinated peptide antibodies (ACPA) and cytokines is of potential importance in the management of patients with rheumatoid arthritis (RA). However,…
Abstract Number: 3016 • 2014 ACR/ARHP Annual Meeting
Measuring the Impact of an Early RA Support and Education Program Using a Program Evaluation with Patient Identified Outcomes
Adena Batterman¹, Kathryn Klingenstein¹, Roberta Horton¹, Linda Leff², Theodore R. Fields³ and Vivian P. Bykerk⁴, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Nursing, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose The Early RA Support and Education Program addresses the unique psycho-educational needs of people recently diagnosed (
Abstract Number: 1960 • 2014 ACR/ARHP Annual Meeting
NF-κB-Inducing Kinase (NIK) Is Expressed in Synovial Endothelial Cells in Early Arthritis Patients and Correlates with Local Disease Activity and Systemic Markers of Inflammation
Karen I. Maijer¹, Ae-Ri Noort², Maria J. H. de Hair¹, Christiaan van der Leij³, Katinka P.M. van Zoest⁴, Danielle M. Gerlag^5,6, Mario Maas³, Paul-Peter Tak^1,7,8 and Sander W. Tas², ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Clinical Immunology & Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶GlaxoSmithKline, Cambridge, United Kingdom, ⁷University of Cambridge, Cambridge, United Kingdom, ⁸GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose The NF-κB family of transcription factors is strongly involved in synovial inflammation. We have previously shown that NF-κB-inducing kinase (NIK) is a key regulator…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…
Abstract Number: 2914 • 2014 ACR/ARHP Annual Meeting
The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Toni Kaegi², Sarah Haile³ and Johannes von Kempis⁴, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose To analyse whether early arthritis patients who do not fulfil the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) have a different course of…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 406 • 2014 ACR/ARHP Annual Meeting
The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis
Fernando Dal Pra¹, Gustavo Citera², Margarita Landi³, Christian A. Waimann⁴, Luis Alejandro Cayetti², Sergio Paira⁵, Federico Ceccatto⁶, Teresita Alvarellos⁷, Luciana Mas⁷, Josefina Marcos⁸, Mercedes García⁸, A Salas⁸, Alejandro Martinez⁹, Rafael Chaparro¹⁰, Oscar Luis Rillo¹¹, Edson Veloso¹², Ricardo V. Juárez¹³, Maria Elena Crespo¹⁴, Antonio Catalán Pellet¹⁵, Anastasia Secco¹⁵, Lucila Marino¹⁶ and V Martire¹⁵, ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Instituto Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital Olavarria, Olavarria, Argentina, ⁵Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁶Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁷Laboratorio de Histocompatibilidad, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ⁸HIGA San Martín, La Plata, Argentina, ⁹Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁰Rheumatology, Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹¹Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹²Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ¹³Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁴Hospital Señor Del Milagro, Salta, Argentina, ¹⁵Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁶Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina
Background/Purpose: Only half of patients with undifferentiated arthritis (UA) will progress to rheumatoid arthritis (RA) after two years of follow-up. Particular human leukocyte antigens class…
Abstract Number: 2845 • 2014 ACR/ARHP Annual Meeting
Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis
Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt, Hendrik Schulze-Koops and Alla Skapenko, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose Whereas T helper (Th) cell subsets were previously regarded as irreversibly differentiated endpoints, evidence suggests that Th cell differentiation is a plastic process in…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 395 • 2014 ACR/ARHP Annual Meeting
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Rachel Audo¹, Claire I. Daien², Laura Papon¹, Cédric Lukas³, O Vittecoq⁴, B Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rouen University Hospital & Inserm U905, Rouen, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France
Background/Purpose : TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear…
Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 1738 • 2014 ACR/ARHP Annual Meeting
Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA
Sandra M.J. Paulissen¹, Jan Piet van Hamburg², Nadine Davelaar², Heleen Vroman³, Johanna MW Hazes⁴, P.H.P. de Jong⁵ and Erik Lubberts², ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Presence of serum anti-citrullinated protein antibodies (ACPAs) in patients with rheumatoid arthritis (RA) predicts worse disease course and a more erosive disease. In the…
Abstract Number: 394 • 2014 ACR/ARHP Annual Meeting
Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort
Susan M. Goodman¹, Yan Ma², Wei Zhang³, Elizabeth Schulman⁴, Janet E. Pope⁵, Carol Hitchon⁶, Susan J. Bartlett⁷, Boulos Haraoui⁸, Daming Lin⁹, Gilles Boire¹⁰, Diane Tin¹¹, J. Carter Thorne¹², Shahin Jamal¹³, Edward C. Keystone¹⁴ and Vivian P. Bykerk^1,15, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research - Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁵St Joseph Health Care, London, ON, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸University of Montreal Hospital Centre, Montreal, QC, Canada, ⁹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ¹³Vancouver General Hospital, Vancouver, BC, Canada, ¹⁴Medicine, University of Toronto, Toronto, ON, Canada, ¹⁵Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To determine if patients with a very low body mass index (BMI) (

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].